Other observed topics

placebo

Observed in 60 articles across 22 journals.

Falling

Latest share0.00%

Change vs baseline-0.14 pp

Months observed11

Latest monthJul 2026

Portfolio article share

Attention over this snapshot

13 monthly points

Journal breadth

Where it appears

Gut9
BMJ Neurology Open6
Journal of Neurology, Neurosurgery & Psychiatry6
Lupus Science & Medicine6
Thorax5
BMJ4
BMJ Open Respiratory Research3
JME Practical Bioethics3
Heart2
Journal of Scleroderma and Related Disorders2
Regional Anesthesia & Pain Medicine2
RMD Open2

Co-occurrence

Explore nearby topics

Inspect the source signal

Article evidence

30 high-ranking examples

Lupus Science & Medicine · 2026-03-01

PO:11:280 Randomized, placebo-controlled, double-blind phase 1b/2 study to explore safety, pharmacokinetics, and initial efficacy of DS-7011a, an anti-toll-like receptor 7 monoclonal antibody, in SLE patients

Phrase rank #2 · DOI 10.1136/lupus-2026-el.334

Gut · 2025-10-06

P181 Safety of seladelpar in patients with primary biliary cholangitis with cirrhosis and clinical signs of portal hypertension: data from the ENHANCE and RESPONSE studies

Phrase rank #3 · DOI 10.1136/gutjnl-2025-BASL.188

Regional Anesthesia & Pain Medicine · 2025-09-10

FT28 Words like medicine

Phrase rank #3 · DOI 10.1136/rapm-2025-ESRA.646

BMJ Open Respiratory Research · 2026-05-07

P25 Placebo effect of mandibular advancement devices

Phrase rank #4 · DOI 10.1136/bmjresp-2026-BSS.49

Gut · 2025-10-06

P30 Treatment with elafibranor has no impact on bone health in patients with primary biliary cholangitis (PBC)

Phrase rank #4 · DOI 10.1136/gutjnl-2025-BASL.46

Gut · 2025-10-06

P35 Change in pruritus in patients with primary biliary cholangitis and moderate to severe pruritus: a pooled analysis from the RESPONSE and ENHANCE studies

Phrase rank #5 · DOI 10.1136/gutjnl-2025-BASL.51

RMD Open · 2026-01-16

A phase III, randomised, double-blind, multi-dose, placebo- and naproxen-controlled study to evaluate the efficacy and safety of fasinumab in patients with pain due to osteoarthritis of the knee or hip

Phrase rank #6 · DOI 10.1136/rmdopen-2025-006436

Journal of Neurology, Neurosurgery & Psychiatry · 2025-11-26

165 Efficacy and safety of rimegepant for the acute treatment of migraine in Japan

Phrase rank #6 · DOI 10.1136/jnnp-2025-ABN.165

Thorax · 2025-11-02

M13 Antibiotic and systemic corticosteroid use in patients with chronic obstructive pulmonary disease and type 2 inflammation receiving dupilumab

Phrase rank #6 · DOI 10.1136/thorax-2025-BTSabstracts.497

Gut · 2025-10-06

P47 Efficacy and safety of seladelpar as monotherapy in patients with primary biliary cholangitis and intolerance to ursodeoxycholic acid

Phrase rank #6 · DOI 10.1136/gutjnl-2025-BASL.63

Journal of Medical Ethics · 2025-09-22

A worthwhile wager: the ethics of open-label placebo treatment in clinical practice

Phrase rank #6 · DOI 10.1136/jme-2024-110270

Archives of Disease in Childhood · 2026-01-19

Obesity, diabetes and glucagon-like peptide-1 receptor agonists

Phrase rank #7 · DOI 10.1136/archdischild-2025-330241

Thorax · 2026-01-15

Cytisinicline for smoking cessation in individuals with self-reported COPD: a post hoc analysis of the ORCA-2 and ORCA-3 trials

Phrase rank #7 · DOI 10.1136/thorax-2025-223880

JME Practical Bioethics · 2025-12-10

Should digital health trials be placebo controlled?

Phrase rank #7 · DOI 10.1136/jmepb-2025-000027

Journal of Neurology, Neurosurgery & Psychiatry · 2025-11-26

25 Assessment of MG-ADL items during a 24-week, phase-3 study (VIVACITY) of nipocalimab in myasthenia gravis

Phrase rank #7 · DOI 10.1136/jnnp-2025-ABN.25

BMJ Neurology Open · 2025-10-23

3457 A stratified analysis of efficacy and safety of fenfluramine in patients with dravet syndrome

Phrase rank #7 · DOI 10.1136/bmjno-2025-ANZAN.46

BMJ Neurology Open · 2025-10-23

3462 Safety and efficacy of frexalimab from the phase 2 open-label extension in participants with relapsing multiple sclerosis: 2-year results

Phrase rank #7 · DOI 10.1136/bmjno-2025-ANZAN.50

BMJ Neurology Open · 2025-09-21

Public and professional attitudes towards deceptive and open-label placebo in functional neurological disorder and wider neurological practice

Phrase rank #7 · DOI 10.1136/bmjno-2025-001171

Journal for ImmunoTherapy of Cancer · 2025-09-08

Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer

Phrase rank #7 · DOI 10.1136/jitc-2025-012555

RMD Open · 2025-08-14

Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study

Phrase rank #7 · DOI 10.1136/rmdopen-2025-005557

Heart · 2026-06-09

418 Anti-inflammatory therapy with Low-dose interleukin-2 (IL-2) in acute coronary syndromes: the results of the IVORY trial and IVORY-FINALE study

Phrase rank #8 · DOI 10.1136/heartjnl-2026-BCS.339

Journal of Neurology, Neurosurgery & Psychiatry · 2025-11-26

6 Nighttime safety of daridorexant: response to noise stimuli, effects on postural stability, walking and memory

Phrase rank #8 · DOI 10.1136/jnnp-2025-ABN.6

Journal of Neurology, Neurosurgery & Psychiatry · 2025-11-26

158 Efficacy and safety of rimegepant for the prevention of migraine in Japan

Phrase rank #8 · DOI 10.1136/jnnp-2025-ABN.158

BMJ · 2025-10-21

Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial

Phrase rank #8 · DOI 10.1136/bmj-2025-084314

Gut · 2025-10-06

P26 Elafibranor improves fatigue versus placebo in patients with primary biliary cholangitis (PBC), with limited correlation with pruritus: analyses from the phase III ELATIVE® trial

Phrase rank #8 · DOI 10.1136/gutjnl-2025-BASL.42

Journal of Neurology, Neurosurgery & Psychiatry · 2025-11-26

124 Fremanezumab for episodic migraine prevention in children and adolescents: efficacy outcomes from a randomised trial

Phrase rank #9 · DOI 10.1136/jnnp-2025-ABN.124

Gut · 2025-10-06

P1 Phase 3 ESSENCE trial evaluating semaglutide in metabolic dysfunction-associated steatohepatitis (MASH): part 1 results and secondary analysis

Phrase rank #9 · DOI 10.1136/gutjnl-2025-BASL.19

Gut · 2025-10-06

O8 Linerixibat significantly improves cholestatic pruritus in primary biliary cholangitis (PBC): results of the pivotal phase 3 GLISTEN trial

Phrase rank #9 · DOI 10.1136/gutjnl-2025-BASL.7

Frontline Gastroenterology · 2026-06-29

OC97 Oral probiotics for the treatment of infantile colic? A systematic review and meta-analysis

Phrase rank #10 · DOI 10.1136/flgastro-2026-bspghan.86

Lupus Science & Medicine · 2026-06-17

Belimumab induces early and sustained resolution of lupus thrombocytopenia

Phrase rank #10 · DOI 10.1136/lupus-2026-002010